English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

N8‐GP (turoctocog alfa pegol, Esperoct ® ; Novo Nordisk A/S, Bagsvaerd, Denmark) is a state‐of‐the‐art, extended half‐life factor VIII (FVIII) molecule used for prophylactic and on‐demand treatment of patients with hemophilia A. The pathfinder clinical trial program, which began with the pathfinder1 trial in 2010, was developed to assess the long‐term efficacy and safety of N8‐GP in children, adolescents, and adults. The pivotal pathfinder2 (adolescents and adults) and pathfinder5 (children) trials were completed in late 2018, and comprehensive analyses of the end‐of‐trial results are published together with this article as part of an N8‐GP Supplement. Furthermore, results from the pathfinder3 trial, which was designed to evaluate the safety and efficacy of N8‐GP during major surgery, have also recently been finalized. Here, we provide an overview of the pathfinder clinical development program and summarize key data from the completed pathfinder trials. We also provide perspectives on the future of extended half‐life FVIII molecules in the treatment of patients with hemophilia A and describe currently ongoing pathfinder trials.

An overview of the pathfinder clinical trials program: Long‐term efficacy and safety of N8‐GP in patients with hemophilia A